Gene-Edited Embryos: A New Push from Origin Genomics

In 2018, Chinese scientist He Jiankui announced the birth of the first gene-edited babies, an act that was widely condemned as reckless and resulted in his imprisonment. The controversy spurred many nations to prohibit germ-line editing of human embryos intended for pregnancy, citing the potential for unintended genetic changes that could be inherited by future generations.

Wired Magazine

Cathy Tie, a 30-year-old biotech entrepreneur and founder of Origin Genomics, launched her company in March with the aim of introducing gene-edited embryos into IVF clinics. In a commentary published in *Trends in Genetics*, Tie argues that advancing this technology is a “moral imperative” and calls for public funding and new regulatory pathways to move edited embryos toward clinical use. She frames the effort as a way to correct devastating genetic mutations permanently.

Wired Magazine

Hank Greely, a law professor and director of the Center for Law and the Biosciences at Stanford University, warns that early human trials have sometimes proceeded without clear safety signals, leading to participant deaths. He emphasizes the risk of “off-target effects,” where unintended DNA edits could introduce new health problems that would also be passed to offspring. These concerns underpin the caution exercised by many governments.

Wired Magazine

Proponents contend that germ-line editing could eradicate hereditary diseases, while critics point to the unknown long-term health consequences for edited children and their descendants. The core unresolved issue is what level of evidence will be deemed sufficient to deem gene-edited embryos safe for pregnancy. Until regulatory frameworks and robust safety data are established, the debate over the moral and scientific justification for moving from laboratory research to clinical application is likely to continue.

Wired Magazine